Elacestrant plus alpelisib in an and co-mutated and heavily pretreated metastatic breast cancer: the first case report for combination efficacy and safety
Breast cancer (BC) is the leading cause of cancer-related mortality among women, and hormone receptor (HR)-positive subtype makes up the majority of all cases. The standard of care in HR + /HER2 − metastatic BC (MBC) is endocrine therapy (ET) plus a CDK4/6 inhibitor (CDK4/6i). ESR1 mutations could i...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-11-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359241297101 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850191466083647488 |
|---|---|
| author | Ünal Metin Tokat Şevval Nur Bilgiç Esranur Aydın Ashkan Adibi Eylül Özgü Onur Tutar Mutlu Demiray |
| author_facet | Ünal Metin Tokat Şevval Nur Bilgiç Esranur Aydın Ashkan Adibi Eylül Özgü Onur Tutar Mutlu Demiray |
| author_sort | Ünal Metin Tokat |
| collection | DOAJ |
| description | Breast cancer (BC) is the leading cause of cancer-related mortality among women, and hormone receptor (HR)-positive subtype makes up the majority of all cases. The standard of care in HR + /HER2 − metastatic BC (MBC) is endocrine therapy (ET) plus a CDK4/6 inhibitor (CDK4/6i). ESR1 mutations could impair the clinical efficacy of the ETs. Similarly, PIK3CA mutations may serve as a negative prognostic marker. Furthermore, MBC is challenging to treat despite new drug approvals. Our patient received multiple lines of ET ± CDK4/6i and chemotherapy but persistently progressed after each or stopped the treatment due to adverse events. Here we showed for the first time that an all-oral combination of elacestrant plus alpelisib was feasible, tolerable, and clinically active in an ESR1 and PIK3CA co-mutated and heavily pretreated patient. We achieved a remarkable response in the metastatic lesions with minor toxicity issues. This case highlights the importance of utilizing up-to-date therapeutic agents and reactive decision-making during personalized cancer treatment. |
| format | Article |
| id | doaj-art-df8be9a73e19472fa218aad7ac6273ef |
| institution | OA Journals |
| issn | 1758-8359 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj-art-df8be9a73e19472fa218aad7ac6273ef2025-08-20T02:14:54ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592024-11-011610.1177/17588359241297101Elacestrant plus alpelisib in an and co-mutated and heavily pretreated metastatic breast cancer: the first case report for combination efficacy and safetyÜnal Metin TokatŞevval Nur BilgiçEsranur AydınAshkan AdibiEylül ÖzgüOnur TutarMutlu DemirayBreast cancer (BC) is the leading cause of cancer-related mortality among women, and hormone receptor (HR)-positive subtype makes up the majority of all cases. The standard of care in HR + /HER2 − metastatic BC (MBC) is endocrine therapy (ET) plus a CDK4/6 inhibitor (CDK4/6i). ESR1 mutations could impair the clinical efficacy of the ETs. Similarly, PIK3CA mutations may serve as a negative prognostic marker. Furthermore, MBC is challenging to treat despite new drug approvals. Our patient received multiple lines of ET ± CDK4/6i and chemotherapy but persistently progressed after each or stopped the treatment due to adverse events. Here we showed for the first time that an all-oral combination of elacestrant plus alpelisib was feasible, tolerable, and clinically active in an ESR1 and PIK3CA co-mutated and heavily pretreated patient. We achieved a remarkable response in the metastatic lesions with minor toxicity issues. This case highlights the importance of utilizing up-to-date therapeutic agents and reactive decision-making during personalized cancer treatment.https://doi.org/10.1177/17588359241297101 |
| spellingShingle | Ünal Metin Tokat Şevval Nur Bilgiç Esranur Aydın Ashkan Adibi Eylül Özgü Onur Tutar Mutlu Demiray Elacestrant plus alpelisib in an and co-mutated and heavily pretreated metastatic breast cancer: the first case report for combination efficacy and safety Therapeutic Advances in Medical Oncology |
| title | Elacestrant plus alpelisib in an and co-mutated and heavily pretreated metastatic breast cancer: the first case report for combination efficacy and safety |
| title_full | Elacestrant plus alpelisib in an and co-mutated and heavily pretreated metastatic breast cancer: the first case report for combination efficacy and safety |
| title_fullStr | Elacestrant plus alpelisib in an and co-mutated and heavily pretreated metastatic breast cancer: the first case report for combination efficacy and safety |
| title_full_unstemmed | Elacestrant plus alpelisib in an and co-mutated and heavily pretreated metastatic breast cancer: the first case report for combination efficacy and safety |
| title_short | Elacestrant plus alpelisib in an and co-mutated and heavily pretreated metastatic breast cancer: the first case report for combination efficacy and safety |
| title_sort | elacestrant plus alpelisib in an and co mutated and heavily pretreated metastatic breast cancer the first case report for combination efficacy and safety |
| url | https://doi.org/10.1177/17588359241297101 |
| work_keys_str_mv | AT unalmetintokat elacestrantplusalpelisibinanandcomutatedandheavilypretreatedmetastaticbreastcancerthefirstcasereportforcombinationefficacyandsafety AT sevvalnurbilgic elacestrantplusalpelisibinanandcomutatedandheavilypretreatedmetastaticbreastcancerthefirstcasereportforcombinationefficacyandsafety AT esranuraydın elacestrantplusalpelisibinanandcomutatedandheavilypretreatedmetastaticbreastcancerthefirstcasereportforcombinationefficacyandsafety AT ashkanadibi elacestrantplusalpelisibinanandcomutatedandheavilypretreatedmetastaticbreastcancerthefirstcasereportforcombinationefficacyandsafety AT eylulozgu elacestrantplusalpelisibinanandcomutatedandheavilypretreatedmetastaticbreastcancerthefirstcasereportforcombinationefficacyandsafety AT onurtutar elacestrantplusalpelisibinanandcomutatedandheavilypretreatedmetastaticbreastcancerthefirstcasereportforcombinationefficacyandsafety AT mutludemiray elacestrantplusalpelisibinanandcomutatedandheavilypretreatedmetastaticbreastcancerthefirstcasereportforcombinationefficacyandsafety |